Clinical Trials Directory

Trials / Completed

CompletedNCT01611181

Iron Substitution After Total Knee Arthroplasty

Iron Substitution After Total Knee Arthroplasty - a Randomized Study

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
72 (actual)
Sponsor
Northern Orthopaedic Division, Denmark · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hemoboost is a registered natural product containing specially processed haemolysed haemoglobin and iron dextran. It is marketed for human use on the basis of many years' use and documented effect in veterinary medicine. Iron dextran was introduced for use in human medicine in 1954. Krauterblut is a registered natural product made from a number of herbs where the active substance is ferrous gluconate. Both drugs have been available for a number of years and have become increasingly popular among patients and healthcare staff due to a reduction in adverse effects. The objective of this study is to determine the effect and adverse effects of the natural products Hemoboost and Kräuterblut compared with the usually administered ferrous sulphate in knee arthroplasty.

Detailed description

Hip and knee arthroplasties are performed with increasing frequency in the western world, and in Denmark approximately 12,000 operations are performed annually (2/1000/year). The perioperative and postoperative blood loss generally constitutes ½ -1½ litres which is frequently associated with symptom-producing anaemia which obstructs mobilisation and increases the risk of complications. Postoperative iron supplementation for a period of up to 12 weeks is therefore a frequently adopted practice. However, there is no consensus or evidence that support postoperative iron supplementation and the effects of iron deficiency are unclear. It is well-known that iron supplementation causes gastrointestinal adverse effects in up to 25% of cases.

Conditions

Interventions

TypeNameDescription
DRUGHemoboost200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
DRUGKräuterblut40 mg iron, 20 ml twice daily.
DRUGFerrofumerat200 mg ferrous sulphate as 1 tablet twice daily.

Timeline

Start date
2006-05-01
Primary completion
2006-12-01
Completion
2007-06-01
First posted
2012-06-04
Last updated
2014-03-31

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT01611181. Inclusion in this directory is not an endorsement.